TY - JOUR T1 - Strategies to examine new compounds for intraperitoneal use in ovarian cancer JF - International Journal of Gynecologic Cancer JO - Int J Gynecol Cancer SP - 33 LP - 35 DO - 10.1111/j.1525-1438.2007.01102.x VL - 18 IS - Suppl 1 AU - M. Markman Y1 - 2008/02/01 UR - http://ijgc.bmj.com/content/18/Suppl_1/33.abstract N2 - The results of three large well-designed randomized trials demonstrating the favorable impact of primary cisplatin-based chemotherapy on survival in small-volume residual advanced ovarian cancer has stimulated considerable interest in exploration of this route of drug delivery for other antineoplastic agents. A number of relevant properties of both the drugs and the peritoneal cavity need to be considered in preclinical evaluation such that future clinical development will focus on strategies that have a realistic potential for being safe and effective when they enter the clinical arena ER -